Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Azithromycin [Design Issues]

posted by kumarnaidu – Mumbai, India, 2016-01-11 13:51 (3821 d 23:18 ago) – Posting: # 15811
Views: 6,351

Dear All,
Recently we did one pilot study on Azithromycin Suspension. In this study we found that the reference drug is showing two peaks. And the study fails for the Cmax. Can anybody suggest what could be the possible reason for getting this kind of concentration curve for reference?

—
Kumar Naidu

Complete thread:

Azithromycin mayur661 2010-06-02 15:05
- Azithromycin Dr_Dan 2010-06-02 15:26
- Azithromycin Helmut 2010-06-02 19:47
  - Azithromycinkumarnaidu 2016-01-11 12:51
    - Azithromycin Dr_Dan 2016-01-12 16:50
      - Azithromycin nobody 2016-01-13 08:21
        
        Azithromycin kumarnaidu 2016-01-13 11:01

Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
301 visitors (0 registered, 301 guests [including 22 identified bots]).
Forum time: 14:09 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas. Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz